KKR-backed JB Pharma acquires cardiac brand rosuvastatin from Glenmark for Rs.314-Cr

PE firm KKR-backed JB Pharma has acquired cardiac brand Razel (rosuvastatin) from Glenmark for the India and Nepal region for INR 314 crore, in an all cash deal. The acquisition will be funded through long term debt and internal accruals. Razel ranks among the top 10 brands in India in the rosuvastatin molecule category, with the combined sales of INR 66.1 crore for the 12 months ended October 2022 as per IQVIA data.